Clinical implications of dynamic determination of plasma long non-coding RNA SOX2-OT in patients with COPD-associated pulmonary hypertension

doi:10.3877/cma.j.issn.1674-6902.2024.06.008

Abstract

Abstract:

Objective

To investigate clinical implications of dynamic determination of plasma long non-coding RNA SOX2-OT in patients with pulmonary hypertension （PH） associated with chronic obstructive pulmonary disease （COPD）.

Methods

It was selected that 120 patients with acute exacerbation of COPD（AECOPD） as the study subjects in our hospital from October 2020 to January 2023.According to the level of pulmonary artery systolic pressure （PASP），the patients were divided into AECOPD group（control group， n=78） and AECOPD-associated PH group （observation group， n=42）.Plasma long non-coding RNA SOX2-OT，interleukin （IL）-6，IL-8，and N-terminal pro brain natriuretic peptide （NT-ProBNP），PASP，arterial blood gas，lung function，and 6-minute walking distance （6MWD） in the two groups were dynamically determined at admission，as well as 10 days，3 months，6 months，and 12 months after admission.Number of times of AECOPD and rates of mortality in the two groups were recorded during the 12 months of follow-up period.

Results

There were statistical differences with respect to 11 variables including the plasma long non-coding RNA SOX2-OT，IL-6，IL-8，and NT-ProBNP，PASP，pH value，PaO₂，PaCO₂，the percentage of forced expiratory volume in one second （FEV₁%），the diffusing capacity for carbon monoxide （DLCO），and 6MWD，between two groups，at admission and 10 days after admission，respectively （all P ＜0.05）.Except for the plasma long non-coding RNA SOX2-OT and PASP，the rest 9 variables 10 days after admission were statistically different from those at admission in the control group （all P＜0.05），whereas all the 11 variables above 10 days after admission were statistically different from those at admission in the observation group （all P＜0.05）.The pairwise comparison among patients at 3-month，6-month，and 12-month demonstrated no statistical significance for all the 11 parameters above in the control group （all P＞0.05）.There were statistical differences in the PASP and plasma levels of long non-coding RNA SOX2-OT and NT-ProBNP （all P＜0.05），while there were no statistical difference in the plasma levels of IL-6 and IL-8（both P＞0.05），when comparing patients at 12-month with those at 3-month and 6-month，respectively，in observation group.There were statistical differences with regard to the pH value，PaO₂，PaCO₂，FEV₁%，DLCO，and 6 MWD，in the pairwise comparisons among patients at 3-month，6-month，and 12-month in the observation group （all P＜0.05）.The mean number of times of AECOPD and mortality rate in the observation group were statistically greater than those in the control group ，respectively，during the 12 months of followup period （both P＜0.05）.

Conclusion

Plasma level of long non-coding RNA SOX2-OT in AECOPD patients with AECOPD-associated PH is significantly higher than that in those without.Dynamic determination of plasma level of long non-coding RNA SOX2-OT has certain clinical implications in the prediction of AECOPD and prognosis of patients with COPD-associated PH.

Key words: Acute exacerbation of chronic obstructive pulmonary disease, Pulmonary hypertension, Long non-coding RNA, SOX2-OT, Prognosis

Chengshi Zhang, Rongrong Chen, Eryun Qin, Qing Zhang, Ming Liu, Qiliang Feng, Yunfeng Zhao. Clinical implications of dynamic determination of plasma long non-coding RNA SOX2-OT in patients with COPD-associated pulmonary hypertension[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(06): 895-900.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2024.06.008

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2024/V17/I06/895

Figures/Tables 2

References 32

1	Wang C，Xu J，Yang L，et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China （the China Pulmonary Health［CPH］ study）：a national cross-sectional study［J］.Lancet，2018，391（10131）：1706-1717.
2	Chaouat A，Naeije R，WeitzenbIum E.Pulmonary hypertension in COPD［J］.Eur Respir J，2008，32（5）：1371-1385.
3	Marc Humbert，Gabor Kovacs，Marius M Hoeper，et al.2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension［J］.Eur Heart J，2022，43（38）：3618-3731.
4	任成山，卞士柱，胡明冬.肺动脉高压的成因及治疗新理念［J/CD］.中华肺部疾病杂志（电子版），2023，16（1）：1-5.
5	Galiè N，Hoeper MM，Humbert M，et al.Guidelines for the diagnosis and treatment of pulmonary hypertension：the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology （ESC） and the european respiratory society（ERS），endorsed by the international society of heart and lung transplantation （ISHLT）［J］.Eur Heart J，2009，30（20）：2493-2537.
6	Gu S，Li G，Zhang X，et al.Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension［J］.Mol Med Rep，2015，11（4）：2631-2643.
7	Wang X，Yan C，Xu X，et al.Long noncoding RNA expression profiles of hypoxic pulmonary hypertension rat model［J］.Gene，2016，579（1）：23-28.
8	Amaral PP，Neyt C，Wilkins SJ，et al.Complex architecture and regulated expression of the Sox2ot locus during vertebrate development ［J］.RNA，2009，15（11）：2013-2027.
9	Jiang Y，Hei B，Hao W，et al.Clinical value of lncRNA SOX2-OT in pulmonary arterial hypertension and its role in pulmonary artery smooth muscle cell proliferation，migration，apoptosis，and inflammatory［J］.Heart Lung，2022，55：16-23.
10	Wang Y，Wu NY，Luo X，et al.SOX2OT，a novel tumor-related long non-coding RNA［J］.Biomed Pharmacother，2020：109725.
11	臧九高，王梅香，沙翔.慢性心力衰竭患者外周血lncRNA SOX2-OT 和miR-2355-3p 表达水平及意义［J］.中南医学科学杂志，2023，51（3）：437-440.
12	Pinto-Plata VM，Cote C，Cabral H，et al.The 6-min walk distance：change over time and value as a predictor of survival in severe COPD［J］.Eur Respir J，2004，23（1）：28-33.
13	Thompson A，Lawrie A.Targeting vascular remodeling to treat pulmonary arterial hypertension［J］.Trends Mol Med，2017，23（1）：31-45.
14	Leopold JA，Maron BA.Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension［J］.Int J Mol Sci，2016，17（5）：761.
15	Gu S，Li G，Zhang X，et al.Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension［J］.Mol Med Rep，2015，11（4）：2631-2643.
16	Wang X，Yan C，Xu X，et al.Long noncoding RNA expression profiles of hypoxic pulmonary hypertension rat model［J］.Gene，2016，579（1）：23-28.
17	Fantes J，Ragge NK，Lynch SA，et al.Mutations in SOX2 cause anophthalmia ［J］.Nat Genet，2003，33（4）：461-463.
18	Askarian-Amiri ME，Seyfoddin V，Smart CE，et al.Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer［J］.PLoS One，2014，9：e102140.
19	Hou Z，Zhao W，Zhou J，et al.A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival［J］.Int J Biochem Cell B，2014，53：380-388.
20	Shahryari A，Rafiee MR，Fouani Y，et al.Two novel splice variants of SOX2OT，SOX2OT-S1，and SOX2OT-S2 are coup regulated with SOX2 and OCT4 in esophageal squamous cell carcinoma ［J］.Stem Cells，2014，32（1）：126-134.
21	Dong H，Zeng L，Wu Y，et al.SOX2-OT/SOX2 axis regulates lung cancer H520 cell migration via Gli1-mediated epithelial-mesenchymal transition［J］.Nan Fang Yi Ke Da Xue Xue Bao，2022，42（10）：1431-1439.
22	Li PY，Wang P，Gao SG，et al.Long noncoding RNA SOX2-OT：Regulations，functions，and roles on mental illnesses，cancers，and diabetic complications［J］.Biomed Res Int，2020，2020：2901589.
23	Tao J，Hu Y.Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis［J］.BMC Cardiovasc Disord，2022，22（1）：211.
24	Wang H，Hu Q，Tong Y，et al.LncRNA SOX2-OT regulates miR-192-5p/RAB2A axis and ERK pathway to promote glioblastoma cell growth［J］.Cell Cycle，2021，20（19）：2010-2020.
25	Yang G，Lin C.Long Noncoding RNA SOX2-OT exacerbates hypoxiainduced cardiomyocytes injury by regulating miR-27a-3p/TGFβR1 axis［J］.Cardiovasc Ther，2020：2016259.
26	Guo Y，Liu Y，Wang H，et al.Long noncoding RNA SRY-box transcription factor 2 overlapping transcript participates in Parkinson's disease by regulating the microRNA-942-5p/nuclear apoptosisinducing factor 1 axis［J］.Bioengineere，2021，12（1）：8570-8582.
27	Wołowiec Ł，Mędlewska M，Osiak J，et al.MicroRNA and incRNA as the future of pulmonary arterial hypertension treatment［J］.Int J Mol Sci，2023，24（11）：9735.
28	Yi C，Gu T，Li Y，et al.Depression of long non-coding RNA SOX2 overlapping transcript attenuates lipopolysaccharide-induced injury in bronchial epithelial cells via miR-455-3p/phosphatase and tensin homolog axis and phosphatidylinositol 3-kinase/protein kinase B pathway［J］.Bioengineered，2022，13（5）：13643-13653.
29	He M，Shen J，Zhang C，et al.Long-chain non-coding RNA metastasisrelated lung adenocarcinoma transcript 1 （MALAT1） promotes the proliferation and migration of human pulmonary artery smooth muscle cells （hPASMCs） by regulating the microRNA-503 （miR-503）/tolllike receptor 4 （TLR4） signal axis［J］.Med Sci Monit，2020，26：e923123.
30	Hui Huang，Limei Yang.Research progress of inflammatory factors in chronic obstructive pulmonary disease with pulmonary hypertension at high altitude［J］.Altern Ther Health Med，2023，29（8）：689-693.
31	张诚实，赵云峰，鲁晓怡，等.血浆鸢尾素在稳定期慢性阻塞性肺病相关肺动脉高压中的临床价值［J］.老年医学与保健，2022，28（1）：140-143.
32	Stubbs HD，Cannon J，Knightbridge E，et al.Sendaway capillary NT-proBNP in pulmonary hypertension［J］.BMJ Open Respir Res，2024，11（1）：e002124.

组别	例数	PASP（mmHg）	血浆长链非编码RNA SOX2-OT	血浆IL-6（pg/ml）	血浆IL-8（pg/ml）	血浆NT-ProBNP（pg/ml）
对照组	78
入院时		35.73±8.52	1.02±0.24	34.22±9.84	26.34±8.36	317.37±86.28
入院10天		31.32±7.74^b	0.94±0.21^b	7.36±2.18^a	11.26±2.59^a	260.25±68.88^a
3月后		28.16±6.58^d	0.92±0.19^d	11.17±3.08^d	14.24±3.27^d	278.52±57.24^d
6月后		32.68±9.14^df	0.93±0.20^df	8.66±2.79^df	16.18±3.35^df	289.35±71.56^df
12月后		33.65±8.11^dfh	0.95±0.23^dfh	13.27±3.17^dfh	13.24±4.09^dfh	321.67±82.36^dfh
观察组	42
入院时		58.34±14.46^a	1.56±0.42^a	66.76±18.23^a	50.36±13.35^a	685.45±154.68^a
入院10天		45.28±10.24^cj	1.21±0.36^cj	24.56±7.26^cj	28.56±7.91^cj	361.24±112.89^cj
3月后		47.33±12.46^ejm	1.25±0.43^ejm	17.34±4.28^fjm	16.25±3.92^fjm	342.46±121.42^ejm
6月后		49.45±14.57^gjmo	1.36±0.41^gjmo	28.65±8.45^gjmo	21.86±5.94^hjmo	375.67±125.78^gjmo
12月后		55.81±16.67^iklnp	1.60±0.46^iklnp	34.71±11.23^ijlnq	31.34±6.56^ijmnq	499.89±138.67^ijmnp

组别	例数	PASP（mmHg）	血浆长链非编码RNA SOX2-OT	血浆IL-6（pg/ml）	血浆IL-8（pg/ml）	血浆NT-ProBNP（pg/ml）
对照组	78
入院时		35.73±8.52	1.02±0.24	34.22±9.84	26.34±8.36	317.37±86.28
入院10天		31.32±7.74^b	0.94±0.21^b	7.36±2.18^a	11.26±2.59^a	260.25±68.88^a
3月后		28.16±6.58^d	0.92±0.19^d	11.17±3.08^d	14.24±3.27^d	278.52±57.24^d
6月后		32.68±9.14^df	0.93±0.20^df	8.66±2.79^df	16.18±3.35^df	289.35±71.56^df
12月后		33.65±8.11^dfh	0.95±0.23^dfh	13.27±3.17^dfh	13.24±4.09^dfh	321.67±82.36^dfh
观察组	42
入院时		58.34±14.46^a	1.56±0.42^a	66.76±18.23^a	50.36±13.35^a	685.45±154.68^a
入院10天		45.28±10.24^cj	1.21±0.36^cj	24.56±7.26^cj	28.56±7.91^cj	361.24±112.89^cj
3月后		47.33±12.46^ejm	1.25±0.43^ejm	17.34±4.28^fjm	16.25±3.92^fjm	342.46±121.42^ejm
6月后		49.45±14.57^gjmo	1.36±0.41^gjmo	28.65±8.45^gjmo	21.86±5.94^hjmo	375.67±125.78^gjmo
12月后		55.81±16.67^iklnp	1.60±0.46^iklnp	34.71±11.23^ijlnq	31.34±6.56^ijmnq	499.89±138.67^ijmnp

组别	例数	pH	PaO₂（mmHg）	PaCO₂（mmHg）	FEV₁%（%）	DLCO（ml/min/mmHg）	6分钟步行距离（m）
对照组	72
入院时		7.33±0.52	68.61±15.82	49.21±12.52	47.21±18.52	17.61±4.82	332.61±87.22
入院10天		7.38±0.47^a	82.33±19.64^a	42.13±9.34^a	67.53±21.44^a	29.63±8.24^a	379.43±90.54^a
3个月后		7.37±0.56^d	76.35±21.46^d	38.35±11.56^d	65.25±19.86^d	26.45±9.16^d	364.85±85.36^d
6个月后		7.38±0.68^df	74.17±18.58^df	43.57±14.58^df	69.27±21.88^df	23.77±6.58^df	381.37±105.28^df
12个月后		7.36±0.41^dfh	75.69±24.50^dfh	44.49±12.97^dfh	68.79±20.63^dfh	25.39±7.55^dfh	372.39±96.30^dfh
观察组	48
入院时		7.25±0.40^a	48.51±13.72^a	73.50±18.69^a	41.11±10.32^a	9.21±2.82^a	254.52±56.21^a
入院10天		7.34±0.45^cj	72.23±15.44^cj	60.58±14.47^cj	58.33±14.94^cj	21.13±6.54^cj	278.24±75.53^cj
3个月后		7.33±0.62^ejm	68.55±14.26^ejm	63.76±18.25^ejm	52.65±13.82^ejm	18.65±5.36^ejm	279.15±66.26^fjm
6个月后		7.31±0.55^gjln	61.37±18.68^gjln	65.64±17.53^gjlo	48.23±15.84^gjln	14.27±4.38^gjln	262.38±62.47^gjln
12个月后		7.25±0.48^iklnp	55.36±12.91^ijlnp	71.34±16.36^iklnp	43.75±12.56^iklnp	10.56±3.18^iklnp	248.24±71.35^iklnp

组别	例数	pH	PaO₂（mmHg）	PaCO₂（mmHg）	FEV₁%（%）	DLCO（ml/min/mmHg）	6分钟步行距离（m）
对照组	72
入院时		7.33±0.52	68.61±15.82	49.21±12.52	47.21±18.52	17.61±4.82	332.61±87.22
入院10天		7.38±0.47^a	82.33±19.64^a	42.13±9.34^a	67.53±21.44^a	29.63±8.24^a	379.43±90.54^a
3个月后		7.37±0.56^d	76.35±21.46^d	38.35±11.56^d	65.25±19.86^d	26.45±9.16^d	364.85±85.36^d
6个月后		7.38±0.68^df	74.17±18.58^df	43.57±14.58^df	69.27±21.88^df	23.77±6.58^df	381.37±105.28^df
12个月后		7.36±0.41^dfh	75.69±24.50^dfh	44.49±12.97^dfh	68.79±20.63^dfh	25.39±7.55^dfh	372.39±96.30^dfh
观察组	48
入院时		7.25±0.40^a	48.51±13.72^a	73.50±18.69^a	41.11±10.32^a	9.21±2.82^a	254.52±56.21^a
入院10天		7.34±0.45^cj	72.23±15.44^cj	60.58±14.47^cj	58.33±14.94^cj	21.13±6.54^cj	278.24±75.53^cj
3个月后		7.33±0.62^ejm	68.55±14.26^ejm	63.76±18.25^ejm	52.65±13.82^ejm	18.65±5.36^ejm	279.15±66.26^fjm
6个月后		7.31±0.55^gjln	61.37±18.68^gjln	65.64±17.53^gjlo	48.23±15.84^gjln	14.27±4.38^gjln	262.38±62.47^gjln
12个月后		7.25±0.48^iklnp	55.36±12.91^ijlnp	71.34±16.36^iklnp	43.75±12.56^iklnp	10.56±3.18^iklnp	248.24±71.35^iklnp

[1]	Wei Liu, Yunfeng Niu, Jie An. LINC01232 promotes malignant progression of triple negative breast cancer through miR-516a-5p/BCL9 axis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 330-338.
[2]	Xiaoyu Zhang, Yulai Yin, Yinxu Zhang. Efficacy and prognostic analysis of apatinib combined with neoadjuvant chemotherapy in triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 346-352.
[3]	Jie Xu, Yajun Li, Junwei Han. Comparison of the efficacy of radical laparoscopic total gastrectomy in the treatment of overweight gastric cancer with two approaches [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 19-22.
[4]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[5]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[6]	Mengjie Liang, Huanhuan Zhu, Xingzhou Wang, Hang Jiang, Shichao Ai, Feng Sun, Peng Song, Meng Wang, Song Liu, Xuefeng Xia, Junfeng Du, Shuang Fu, Xiaofeng Lu, Xiaofei Shen, Wenxian Guan. Analysis of prognosis and postoperative complications of gastric cancer patients undergoing conversion therapy with combined immunotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 619-623.
[7]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[8]	Xiangyu Qu, Yigang Zhang, Haoling Li, Tian Qiu, Yi Tan. Diagnostic and prognostic role of USP24 and its co-expression of tumor metabolic genes in hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 659-662.
[9]	Wen Gu, Shouxin Ling, Haili Tang, Xuemei Gan. Comparison of two different surgical approaches for open radical surgery in patients with papillary thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 687-690.
[10]	Chengwang Fu, Dagang Yang, Rong Wang, Futang Li. Research progress of nutritional and inflammatory markers in resectable pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 704-708.
[11]	Wei Li, Zijian Song, Yancheng Lai, Rui Zhou, Han Wu, Longxin Deng, Rui Chen. The current state and prospects of artificial intelligence applied to prognosis prediction in prostate cancer patients [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 541-546.
[12]	Zun Chen, Ping Wang, Hua Jin, Meiling Zhou, Qingqing Li, Yonggang Huang. Application of sarcopenia in predicting incisional hernia after colorectal cancer surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 639-644.
[13]	Yan Wang, Meiling Sun, Lingfeng Min. Identification of CA9，an iron death-related gene in lung adenocarcinoma based on the TCGA database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(06): 888-894.
[14]	Jiagang Han, Zhenjun Wang. The treatment strategies for obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 450-458.
[15]	Zhaorong Guo, Xinguang Wang, Yiqiang Liu, Yingjian He, Lize Wang, Yang Yang, Xing Wang, Wei Cao, Chongshan Gu, Tie Fan, Jinfeng Li, Zhaoqing Fan. Clinicopathologic characteristics and prognostic risk factors of different subtypes of phyllodes tumor of the breast [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 524-532.

Please choose a citation manager

Content to export